Informations sur le stock Agios Pharmaceuticals | Filter  Basic-Info

Agios Pharmaceuticals

Past year was a negative year for Agios Pharmaceuticals investors

The stock lost over the past 12 months at around 29 percent. Over the past 5 years Agios Pharmaceuticals' stock lost at around 0 percent in value. Agios Pharmaceuticals's revenues between 2011 and 2015 were very volatile through the time and moved between 25,11 million dollars and 59,12 million dollars. Agios Pharmaceuticals's net results between 2011 and 2015 were far from constant and moved between -23,71 million dollars and -117,73 million dollars.

Agios Pharmaceuticals's head office is based in Cambridge. Agios Pharmaceuticals mainly operates in the pharmaceutical sector. Dr. David P. Schenkein M.D is the company' CEO. Mr. Glenn Goddard(SVP Finnance) runs the company as a CFO. The period from 2006 till the end of 2016 the international sector gained around 75 percent. As from 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

Agios Pharmaceuticals didn't pay out any dividends (in the past 5 years).

Agios Pharmaceuticals's balance mostly consists of debt

As per the end of 2015 the American company's balance sheet equaled 420,07 million dollars. The total debt was around 74,95 million dollars. This is 17,84 percent of the total balance sheet. At the end of 2016 the American company was traded with a price/earnings-ratio of around -36. So investors paid -36 times the company's 2015's EPS. We could say that based on her price/earnings-ratio and dividend yield the American stock can be seen as a growth stock.

At the end of 2015 the pharmaceutical company's market size (her number of outstanding share times the stock price) equaled around 2,38 billion dollars. At the end of 2015 around 37,43 million stocks were listed.

All Agios Pharmaceuticals's financial reports are located here. More information about Agios Pharmaceuticals can be found it's website. .